Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
Copyright © 2020 the Author(s). Published by PNAS..
Glucagon-like peptide-1 receptor (GLP-1R) agonists are efficacious antidiabetic medications that work by enhancing glucose-dependent insulin secretion and improving energy balance. Currently approved GLP-1R agonists are peptide based, and it has proven difficult to obtain small-molecule activators possessing optimal pharmaceutical properties. We report the discovery and mechanism of action of LY3502970 (OWL833), a nonpeptide GLP-1R agonist. LY3502970 is a partial agonist, biased toward G protein activation over β-arrestin recruitment at the GLP-1R. The molecule is highly potent and selective against other class B G protein-coupled receptors (GPCRs) with a pharmacokinetic profile favorable for oral administration. A high-resolution structure of LY3502970 in complex with active-state GLP-1R revealed a unique binding pocket in the upper helical bundle where the compound is bound by the extracellular domain (ECD), extracellular loop 2, and transmembrane helices 1, 2, 3, and 7. This mechanism creates a distinct receptor conformation that may explain the partial agonism and biased signaling of the compound. Further, interaction between LY3502970 and the primate-specific Trp33 of the ECD informs species selective activity for the molecule. In efficacy studies, oral administration of LY3502970 resulted in glucose lowering in humanized GLP-1R transgenic mice and insulinotropic and hypophagic effects in nonhuman primates, demonstrating an effect size in both models comparable to injectable exenatide. Together, this work determined the molecular basis for the activity of an oral agent being developed for the treatment of type 2 diabetes mellitus, offering insights into the activation of class B GPCRs by nonpeptide ligands.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:117 |
|---|---|
| Enthalten in: |
Proceedings of the National Academy of Sciences of the United States of America - 117(2020), 47 vom: 24. Nov., Seite 29959-29967 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kawai, Takahiro [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.01.2021 Date Revised 19.01.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1073/pnas.2014879117 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317448315 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317448315 | ||
| 003 | DE-627 | ||
| 005 | 20231225163307.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1073/pnas.2014879117 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1058.xml |
| 035 | |a (DE-627)NLM317448315 | ||
| 035 | |a (NLM)33177239 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kawai, Takahiro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.01.2021 | ||
| 500 | |a Date Revised 19.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 the Author(s). Published by PNAS. | ||
| 520 | |a Glucagon-like peptide-1 receptor (GLP-1R) agonists are efficacious antidiabetic medications that work by enhancing glucose-dependent insulin secretion and improving energy balance. Currently approved GLP-1R agonists are peptide based, and it has proven difficult to obtain small-molecule activators possessing optimal pharmaceutical properties. We report the discovery and mechanism of action of LY3502970 (OWL833), a nonpeptide GLP-1R agonist. LY3502970 is a partial agonist, biased toward G protein activation over β-arrestin recruitment at the GLP-1R. The molecule is highly potent and selective against other class B G protein-coupled receptors (GPCRs) with a pharmacokinetic profile favorable for oral administration. A high-resolution structure of LY3502970 in complex with active-state GLP-1R revealed a unique binding pocket in the upper helical bundle where the compound is bound by the extracellular domain (ECD), extracellular loop 2, and transmembrane helices 1, 2, 3, and 7. This mechanism creates a distinct receptor conformation that may explain the partial agonism and biased signaling of the compound. Further, interaction between LY3502970 and the primate-specific Trp33 of the ECD informs species selective activity for the molecule. In efficacy studies, oral administration of LY3502970 resulted in glucose lowering in humanized GLP-1R transgenic mice and insulinotropic and hypophagic effects in nonhuman primates, demonstrating an effect size in both models comparable to injectable exenatide. Together, this work determined the molecular basis for the activity of an oral agent being developed for the treatment of type 2 diabetes mellitus, offering insights into the activation of class B GPCRs by nonpeptide ligands | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a LY3502970 | |
| 650 | 4 | |a OWL833 | |
| 650 | 4 | |a cryoelectron microscopy | |
| 650 | 4 | |a glucagon-like peptide-1 receptor | |
| 650 | 4 | |a type 2 diabetes mellitus | |
| 650 | 7 | |a Aminopyridines |2 NLM | |
| 650 | 7 | |a Anti-Obesity Agents |2 NLM | |
| 650 | 7 | |a Benzamides |2 NLM | |
| 650 | 7 | |a GLP1R protein, human |2 NLM | |
| 650 | 7 | |a Glp1r protein, mouse |2 NLM | |
| 650 | 7 | |a Glucagon-Like Peptide-1 Receptor |2 NLM | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Incretins |2 NLM | |
| 650 | 7 | |a PF-06372222 |2 NLM | |
| 650 | 7 | |a Tryptophan |2 NLM | |
| 650 | 7 | |a 8DUH1N11BX |2 NLM | |
| 700 | 1 | |a Sun, Bingfa |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshino, Hitoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Yoshiyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Fukazawa, Masanori |e verfasserin |4 aut | |
| 700 | 1 | |a Nagao, Shunsuke |e verfasserin |4 aut | |
| 700 | 1 | |a Wainscott, David B |e verfasserin |4 aut | |
| 700 | 1 | |a Showalter, Aaron D |e verfasserin |4 aut | |
| 700 | 1 | |a Droz, Brian A |e verfasserin |4 aut | |
| 700 | 1 | |a Kobilka, Tong Sun |e verfasserin |4 aut | |
| 700 | 1 | |a Coghlan, Matthew P |e verfasserin |4 aut | |
| 700 | 1 | |a Willard, Francis S |e verfasserin |4 aut | |
| 700 | 1 | |a Kawabe, Yoshiki |e verfasserin |4 aut | |
| 700 | 1 | |a Kobilka, Brian K |e verfasserin |4 aut | |
| 700 | 1 | |a Sloop, Kyle W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Proceedings of the National Academy of Sciences of the United States of America |d 1915 |g 117(2020), 47 vom: 24. Nov., Seite 29959-29967 |w (DE-627)NLM000008982 |x 1091-6490 |7 nnns |
| 773 | 1 | 8 | |g volume:117 |g year:2020 |g number:47 |g day:24 |g month:11 |g pages:29959-29967 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1073/pnas.2014879117 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 117 |j 2020 |e 47 |b 24 |c 11 |h 29959-29967 | ||